HOME >> BIOLOGY >> NEWS
Mayo Clinic develops blood vessel cells from adult progenitor cells

ROCHESTER, Minn. -- Mayo Clinic scientists have shown for the first time that an adult stem cell variant circulating in adult human blood can be driven to form smooth muscle cells, which are key building blocks in blood vessel formation and also participate in coronary artery blockages. The findings are published in this week's edition of Circulation, the journal of the American Heart Association, and will be presented simultaneously at the European Society of Cardiology conference in Berlin.

The researchers used platelet-derived growth factor BB (PDGF-BB) to convert previously undiscovered circulating smooth muscle progenitor cells (SPCs) into smooth muscle outgrowth cells (SOCs). SPCs produced presumably reside in the bone marrow and are stem cells that have started down the path of cell differentiation. Scientists had suspected the existence of circulating SPCs because animal studies had shown that many smooth muscle cells found in atherosclerotic plaques or in restenosis after angioplasty had been partially derived from bone marrow.

The Mayo Clinic study is the first to prove the existence of SPCs in humans. In the presence of PGDF-BB, the cells rapidly proliferated into smooth muscle cells. These cells also had adhesive properties potentially steering the cells to areas of vessel blockages. According to first author, David Simper, M.D., the study may be a significant step in the potential development of new vessels (angiogenesis) to provide blood circulation to diseased hearts. "Previous studies have shown that endothelial cells, which line blood vessels can be grown from progenitors in blood," says Dr. Simper. "Smooth muscle cells are the essential building blocks of arteries, and until now we have not had a way to create them".

These new findings may help cardiologists address in a new way some of the key problems in interventional cardiology. "About 30 percent of patients with heart disease who have stents implanted during a
'"/>

Contact: Lee Aase
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Sep-2002


Page: 1 2

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Hope Clinic of Emory Vaccine Center receives CDC contract
3. Clinical judgement still counts strongly alongside genetic testing
4. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
5. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
6. St. Jude/Mayo Clinic study finds direct link between CBP gene and lymphoma
7. DFG to establish seven new Clinical Research Units
8. Clinical trial patients dont care about study sponsors or physician conflicts of interest
9. NIH establishes Rare Diseases Clinical Research Network
10. Grant strengthens research arm of Penn State Hershey Medical Centers ALS Clinic
11. Clinical study reports findings of combination therapy with DOXIL

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mayo Clinic develops blood vessel cells from adult progenitor cells

(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
Cached News: